DUBLIN, June 16, 2020 /PRNewswire/ -- The "CAR-T Therapy Market Global Report 2020-30" report has been added to ResearchAndMarkets.com's offering.

The global CAR-T therapy market was worth $611.31 million in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 51.10% and reach $3,186.23 million by 2023. North America is expected to be the largest region in the forecast period.

The CAR-T therapy market is driven by the increasing financial support provided by different organizations to promote the development and consumption of CAR-T therapy. The government and non-government organizations provide financial support to the companies in CAR-T therapy market for research and development and to the patients for their treatment of acute lymphoblastic leukaemia (ALL). For instance, in 2019, the Ministry of Business, Innovation and Employment of New Zealand announced its contribution of $4.9 million over 5 years to its partnership scheme with Malaghan Institute (MI), in order to support the development of CAR T-cell manufacturing in New Zealand. Further, governments in some countries provide subsidy to patients undergoing CAR-T therapy owing to the high cost of the treatment. For example, in 2019, the government of Australia included the CAR-T therapy on the Medicare Benefits Schedule (MBS). The inclusion of (Kymriah) CAR-T therapy in MBS reduces the cost of the treatment for almost 30 paediatric and young adult (ALL) patients per year in Australia. The financial support provided by different organizations towards CAR-T therapy positively drives the growth of CAR-T therapy market.

The limitations on the application of CAR-T therapy limits the growth of the market. The limitations on CAR-T therapy includes its failure to treat other types of cancer, side effects and the high cost of treatment. CAR-T therapy is widely used as a treatment for a particular type of blood cancer and fails to treat other types of cancers such as lung cancer or breast cancer. Further, in many cases the application of CAR-T therapy results in cytokine release syndrome (CRS). CRS is severe flu like condition causing high fever, nausea, chills, headache, rash, and troubled breathing. Further, the high cost limits the growth of the market. According to an article in HealthLeaders in 2019, the cost of one CAR-T therapy session can be up to $375,000 excluding the overhead charges such as hospital bills. Thus, the growth of the CAR-T therapy is restricted by the various limitations on the application of CAR-T therapy.

The companies in the CAR-T therapy market are conducting clinical trials to assess the ability of CAR-T therapy to treat multiple myeloma. Multiple myeloma is a type of white blood cell cancer where the cancer cells accumulate in the bone marrow and surrounds the healthy blood cells. CAR-T therapy is being tested as a treatment for multiple myeloma. CAR-T cells are modified to target the multiple myeloma causing cells to treat the relapsed or refractory multiple myeloma (RRMM). For instance, Sorrento Therapeutics, a USA based developer of therapeutic approaches to treat different types of cancer, developed CAR2 anti-CD38 CAR-T cell therapy to treat RRMM. The CAR2 anti-CD38 CAR-T cell therapy is in phase 1 of its clinical trial with 72 participant recruitments made by the end of 2019.The aim of the clinical trial is to evaluate the efficiency and safety of CAR2 anti-CD38 CAR-T cell therapy. The trial is expected to be completed in 2020.

In 2019, Novartis, a Switzerland based global medicines company, acquired CellforCure for an undisclosed amount. The acquisition is aimed to increase Novartis' internal production capacity for cell and gene therapies. CellforCure is a French based contract development and manufacturing organization (CDMO) that provides manufacturing facility for cell and gene therapy. CellforCure assisted Novartis in 2017 to manufacture CAR-T treatment named Kymriah.

Major players in the market are Novartis AG, Kite Pharma, Pfizer Inc, Juno Therapeutics, Celgene Corporation, CARsgen Therapeutics, Sorrento Therapeutics and Legend Biotech.

Report Scope

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider car-t therapy market, and compares it with other markets.

Key Topics Covered

1. Executive Summary

2. CAR-T therapy Market Characteristics

3. CAR-T therapy Market Size And Growth 3.1. Global CAR-T therapy Historic Market, 2015 - 2019, $ Billion 3.1.1. Drivers Of The Market 3.1.2. Restraints On The Market 3.2. Global CAR-T therapy Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion 3.2.1. Drivers Of The Market 3.2.2. Restraints On the Market

4. CAR-T therapy Market Segmentation 4.1. Global CAR-T therapy Market, Segmentation By Target Antigen, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

4.2. Global CAR-T therapy Market, Segmentation By Application, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

5. CAR-T therapy Market Regional And Country Analysis 5.1. Global CAR-T therapy Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion 5.2. Global CAR-T therapy Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/d7jbji

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

View post:
CAR-T Therapy Market Outlook to 2030 by Target Antigen, Application, Region, Country and Company - PRNewswire

Recommendation and review posted by Bethany Smith

Dublin, June 15, 2020 (GLOBE NEWSWIRE) -- The "Global Gene Therapy Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies

The report provides a detailed understanding and analysis of how and why companies enter gene therapy partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.

This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.

Key Topics Covered:

Chapter 1 - Introduction

Chapter 2 - Trends in Gene therapy dealmaking2.1. Introduction2.2. Gene therapy partnering over the years2.3. Most active Gene therapy dealmakers2.4. Gene therapy partnering by deal type2.5. Gene therapy partnering by therapy area2.6. Deal terms for Gene therapy partnering

Chapter 3 - Leading Gene therapy deals3.1. Introduction3.2. Top Gene therapy deals by value

Chapter 4 - Most active Gene therapy dealmakers4.1. Introduction4.2. Most active Gene therapy dealmakers4.3. Most active Gene therapy partnering company profiles

Chapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directory

Chapter 6 - Gene therapy dealmaking by technology type

Chapter 7 - Partnering resource center

A selection of the companies mentioned include:

For more information about this report visit https://www.researchandmarkets.com/r/6xcnxy

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Link:
Gene Therapy Global Partnering Terms and Agreements Directory of Deals by the World's Leading Healthcare Companies from 2014-2020 - Yahoo Finance UK

Recommendation and review posted by Bethany Smith

The global Gene Therapy for Rare Disease Market research report thoroughly explains each and every aspect related to the Gene Therapy for Rare Disease Market, which facilitates the reports reader to study and evaluate the upcoming market trend and execute the analytical data to promote the business. The growth trend forecasted on account of a thorough examination offers in-depth information regarding the global Gene Therapy for Rare Disease Market. A pathway of development is offered by the market to the several connected networks of businesses under it, which include different firms, industries, organizations, vendors, distributors, and local manufacturers too. All the key Gene Therapy for Rare Disease Market players compete with each other by offering better products and services at a reasonable price in order to grab significant share at the regional and global level market.

Get a Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2321

This report sample includesBrief Introduction to the research report.Table of Contents (Scope covered as a part of the study)Top players in the marketResearch framework (presentation)Research methodology adopted by Coherent Market Insights

The report incorporates an estimated impact of strict standards and regulations set by the government over the market in the upcoming years. The market report also comprises exhaustive research done using several analytical tools such as SWOT analysis to identify the market growth pattern.

Top Manufacturers in GlobalGene Therapy for Rare DiseaseMarket Includes:Kite Pharma, Inc. (Gilead Sciences, Inc.), Novartis International AG, Juno Therapeutics Inc. (Celgene Corporation), Bluebird Bio, Inc., Spark Therapeutics, Inc., uniQure N.V, Orchard Therapeutics Plc., PTC Therapeutics, Inc., and BioMarin Pharmaceutical Inc.

Regions & Countries Mentioned In The Gene Therapy for Rare Disease Market Report:

Key Highlights of the Table of Contents:

Gene Therapy for Rare Disease Market Study Coverage: It includes key manufacturers covered, key market segments, the scope of products offered in the global market, years considered, and study objectives. Furthermore, it tuches the segmentation study provided in the report on the basis of the type of product and applications.

Gene Therapy for Rare Disease Market Executive Summary: This section emphasizes on the key studies, market growth rate,Competitive landscape, market drivers, trends, and issues.

Gene Therapy for Rare Disease Market Production by Region: The report provides information related to import and export, production, revenue, and key players of all regional markets studied are covered in this section.

Gene Therapy for Rare Disease Market Profile of Manufacturers: Analysis of each market player profiled is detailed in this section. This also provides SWOT analysis, products, production, value, capacity, and other vital factors of the individual player.

Buy This Complete A Business Report: https://www.coherentmarketinsights.com/insight/buy-now/2321

Table of Contents

Report Overview:It includes the Gene Therapy for Rare Disease market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary:This section of the report gives information about Gene Therapy for Rare Disease market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players:Here, key players of the Gene Therapy for Rare Disease market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study:All of the regions and countries analyzed in the Gene Therapy for Rare Disease market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Get Download PDF Brochure https://www.coherentmarketinsights.com/insight/request-pdf/2321

Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

About CMI:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights 1001 4th Ave,#3200 Seattle, WA 98154, U.SPhone: US +12067016702 / UK +4402081334027Email: [emailprotected]

Visit link:
Gene Therapy for Rare Disease Market: Top Global Players Competition with Production, Consumption, Revenue and Gross Margin by 2026 - Medic Insider

Recommendation and review posted by Bethany Smith

BDRP Virtual Annual Meeting

RESTON, Va. (PRWEB) June 16, 2020

Some of the worlds leading scientists will be recognized for their research on birth defects, including alcohol and cannabinoid exposure on brain development, caffeine exposure during pregnancy, and gene-environmental interactions in autism. The special lectures and awards will be presented at the Society for Birth Defects Research and Preventions (BDRP) first-ever Virtual Annual Meeting June 25, 29 and 30, as well as July 1 and 2, 2020.

At a fraction of the cost of its traditional in-person Annual Meeting, the BDRP virtual presentations will also cover other hot topics such as the latest birth defects research surrounding opioids, gene therapy, and obesity in pregnancy. For the full Virtual Annual Meeting schedule, including opportunities for Continuing Medical Education credits, please visit https://birthdefectsresearch.org/meetings/2020/.

The Society for Birth Defects Research and Prevention is an international and multidisciplinary group of scientists including researchers, clinicians, epidemiologists, and public health professionals from academia, government, and industry who study birth defects, reproduction, and disorders of developmental origin. Through its 2020 awards, the unique diversity of the birth defects research field is underscored. Our foundation as a multi-disciplinary society led the way for innovative research that continues to move us toward a healthier future, said Chris Curran, PhD, BDRP President. As scientists, we have always recognized the transformative power of diversity in the many disciplines represented in the Society and we hope to inspire more scientists of all backgrounds to get involved in this rewarding research.

The 2020 Society for Birth Defects Research and Prevention award recipients and special lecturers include:

Keynote LectureDiana W. Bianchi, MD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Scheduled Presentation: Prenatal Genomic Medicine: Transforming Obstetric Practice and Delivering New Biological Insights

Josef Warkany Lecture Linda S. Birnbaum, PhD, DABT, ATS, Scientist Emeritus and Former Director, National Institute of Environmental Health Sciences and National Toxicology ProgramScheduled Presentation: POPs: A Plethora of Developmental Effects

Robert L. Brent Lecture: Teratogen UpdateKaren W. Gripp, MD, FAAP, FACMG, A.I. duPont Hospital for Children/NemoursScheduled Presentation: From Dysmorphology to Next-Generation Phenotyping

F. Clarke Fraser New Investigator Award Joshua F. Robinson, PhD, University of California, San FranciscoScheduled Presentation: Establishing a Research Program in Developmental Toxicology Utilizing In Vitro Models and Big Data Approaches

Agnish Fellowship Elaine M. Faustman, PhD, University of WashingtonScheduled Presentation: Educating Future Birth Defects Researchers: Opportunities in the Era of Personalized Medicine, Systems Biology, and CRISPR Technologies

James G. Wilson Publication Award for the best paper published in the journal Birth Defects ResearchKristen R. Breit, PhD, San Diego State University The effects of alcohol and cannabinoid exposure during the brain growth spurt on behavioral development in rats; Birth Defects Research 111.12: 760-774 (2019)

Society for Birth Defects Research and Prevention Innovator Award Finalists

Title: ReproTracker: A Human Stem Cell-Based Biomarker Assay for In Vitro Assessment of Developmental Toxicity.

Title: Studying Gene-Environmental Interactions in Autism with iPSC-derived BrainSpheres: microRNA and Metabolic Biomarkers of the Synergy.

Edward W. Carney Distinguished Service Award Alan M. Hoberman, PhD, DABT, ATS, Charles River

Marie W. Taubeneck AwardBevin Blake, PhD, NTPL/NIEHS

Edward W. Carney Trainee Awards

FASEB Howard Garrison Public Affairs FellowshipMona Dai, PhD Student, Harvard University

Birth Defects Research Distinguished Scholar Awards

For a full list of Society for Birth Defects Research and Prevention awards and recipients, please visit: https://www.birthdefectsresearch.org/meetings/2020/am-awards.asp

About the Society for Birth Defects Research and PreventionThe Society for Birth Defects Research and Prevention (BDRP) is made up of nearly 700 members worldwide specializing in a variety of disciplines, including developmental biology and toxicology, reproduction and endocrinology, epidemiology, cell and molecular biology, nutritional biochemistry, and genetics as well as the clinical disciplines of prenatal medicine, pediatrics, obstetrics, neonatology, medical genetics, and teratogen risk counseling. Scientists interested in BDRP membership are encouraged to visit http://www.BirthDefectsResearch.org.

Media Contact: Nicole Chavez, 619-368-3259, nchavez@birthdefectsresearch.org

Continue reading here:
Diverse Birth Defects Research and the Science of Tomorrow to Be Recognized by the Society for Birth Defects Research and Prevention - PR Web

Recommendation and review posted by Bethany Smith

New Jersey, United States,- A detailed research study on Hemophilia Gene Therapy Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Hemophilia Gene Therapy, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=274190&utm_source=COD&utm_medium=888

Leading Hemophilia Gene Therapy manufacturers/companies operating at both regional and global levels:

Hemophilia Gene Therapy Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Hemophilia Gene Therapy market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Hemophilia Gene Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Hemophilia Gene Therapy Market, By Product

Hemophilia Gene Therapy Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=274190&utm_source=COD&utm_medium=888

Hemophilia Gene Therapy Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Hemophilia Gene Therapy market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Hemophilia Gene Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Hemophilia Gene Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Hemophilia Gene Therapy Market, By Deployment Model

5.1 Overview

6 Hemophilia Gene Therapy Market, By Solution

6.1 Overview

7 Hemophilia Gene Therapy Market, By Vertical

7.1 Overview

8 Hemophilia Gene Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Hemophilia Gene Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=274190&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Acoustic Emission Testing Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Construction Robot Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Electric Commercial Vehicle Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

The rest is here:
Hemophilia Gene Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

With the coronavirus pandemic forcing scientific research labs to close around the globe, it seems almost inevitable that the ongoing crisis will accelerate the growing demand for remote drug development. A number of European companies see this as an opportunity to introduce computer-aided biology and robot-driven labs.

In recent years, the pharmaceutical industry has been increasingly struggling with the rising costs of developing new drugs due to factors ranging from the complexity of diseases like cancer to stringent regulatory hurdles. Now, in a bid to boost the productivity of R&D pipelines and reduce costs, new technologies are promising to automate traditionally laborious and time-consuming tasks in the drug development process.

In the same way that Amazon Web Services changed the software industry by allowing businesses to outsource their entire IT infrastructure, several European biotechs are developing technology that allows labs to automatically conduct and analyze biological experiments in remote robotic labs.

A survey conducted in April suggested that 48% of scientific research labs across the globe had been forced to close temporarily due to the ongoing coronavirus pandemic. Hence, the crisis could accelerate the uptake of automation technology in research labs.

There has already been a shift towards computer-aided biology for the last 18 months, explained Peter Crane, corporate strategy manager at Synthace, one of the biotechs developing such technology.

Covid-19 has acted as an accelerant. Synthace has seen an increasing interest in our approach, and we expect this will continue to grow more rapidly post Covid-19. There has been a huge amount of disruption caused by Covid-19, and we believe that once this has eased, people will seriously begin to re-evaluate how they are conducting their science, and there will be a market bump regarding the adoption of new technologies within pharma and academia.

Over the past two decades, industries such as the semiconductor and automotive sectors have increasingly embraced next-generation automation technologies as a means of reducing costs while simultaneously increasing product complexity.

Crane pointed out that in this regard, the biotechnology industry as a whole currently lags behind. While automation is used to a certain extent, it is mainly at the two extreme ends of the drug development process, both in repeatedly screening thousands of compounds against a drug target and in manufacturing the finished product.

[There] is this huge middle bit where experiments are still done at the bench, he said. But were seeing interest from people looking at how they can use technology to get more done with fewer people in the lab.

This is mainly because designing and carrying out such experiments is a highly dynamic process, one which has previously been beyond the realm of machines. However, recent advances in machine learning and robotic systems offer new possibilities.

Synthaces cloud software platform which is already being used by companies in Europe and the US, including Merck and Microsoft enables scientists to design experimental protocols from their laptops via a graphical user interface. These are then converted into instructions that a robot can understand, and transmitted to a remote lab.

While a technician is still required to set up the robot with the reagents and labware specified in the experimental design, the vast majority of the process is done virtually. Once the experiment is completed, the data is automatically collated, structured, and returned to the user.

Likewise, UK-based biotech Arctoris has also designed a platform that enables scientists to simulate and then run a range of experiments in a remote robotic lab. In the eyes of Arctoris co-founder and CEO, Martin-Immanuel Bittner, the flexibility offered by this kind of technology will make it far easier for budding entrepreneurs to bring new concepts to the market.

It enables any researcher worldwide to start a biotech company with a laptop and a credit card, said Bittner. You dont need a lab anymore, you dont have to worry about equipment purchases and maintenance. So instead of restricting drug discovery research to a few centers that can afford all the specialist equipment, we enable the brightest minds to contribute to the enormous challenges that we are facing in chronic illnesses such as cancer, heart disease, and neurodegeneration.

As well as saving time and cost, the other main advantage of automating experiments comes from reducing human error, and so consistently generating reliable data. With regulatory and due diligence standards in drug development becoming ever more stringent, generating high quality and fully auditable data has never been more important.

Bittner said that there is already evidence to suggest that automating experiments and data collation processes can make it easier for companies to attract early-stage venture capital funding.

Several of our clients have told us that the VCs they spoke with for their next funding round put a lot of emphasis on whether the data they showed to back up their hypotheses was trustworthy or not, he explained. In this context, automated data collection allows a full audit of every step taken.

In a regulated environment such as biopharma, it is absolutely critical to be able to demonstrate to regulators what happened when. We enable that down to the minute an experiment was conducted.

Eliminating human error could help tackle one of the root causes of the declining productivity in drug discovery in recent decades, which is a lack of reproducibility. Only 10 to 20% of all published laboratory findings can be reproduced by independent third parties, wasting billions in R&D funding, said Bittner. This has a devastating effect. Automation could get around this issue by ensuring that experiments are conducted in exactly the same way no matter how long apart.

Two sectors where automation could have the biggest impact in the decade to come are the growing cell and gene therapy industries. While both have been heralded as a means to cure many of the worlds rare diseases, the sheer cost of such therapies has so far been prohibitive. To give just one example, a gene therapy for spinal muscular atrophy developed by Novartis is currently sold at $2.1 million in the US.

Automating the mechanics of treatments based on genetic engineering techniques such as CRISPR gene editing could make it possible for companies to scale up the production of such therapies on demand, which could dramatically reduce the cost.

Synthego, a company working on automating genome engineering, has declared its intention to ultimately make cell and gene therapies as accessible as vaccines.

Our primary goal with Synthego is to break through the barriers to entry for world-class quality life science research, said Paul Dabrowski, CEO of Synthego. Our platform minimizes the variables and risks in biological research by automating workflows, controlling quality, scaling for massive experiments, and reducing cost structures.

Synthego has built a suite of genome editing products that allow any scientist to outsource their CRISPR needs and use these molecular tools without needing to be an expert in the area themselves, thus opening up the field to a much broader range of researchers. For example, one of their packages enables researchers to get a gene knockout in one of several hundred cell lines.

In the coming years, the company intends to offer more complex modifications, enabling both academia and industry to access CRISPR gene editing while continuing to focus on their specific area of expertise.

Its empowering cell biologists with the tools of molecular biology without having to learn all those details, said Dabrowski. This is following the model of cloud technology, where companies rent out remote server farms to handle their computing needs instead of relying on their own hardware. Well be able to do their full research workflow.

All in all, there seems to be no doubt that the Covid-19 pandemic will change the face of drug discovery and development. As researchers around the globe are faced with remote work, automation technology for biology laboratories seem to have reached their time to shine and change the way drug development is done.

Cover illustration by Anastasiia Slynko, images via Shutterstock and Synthego

Read more:
Drug Development in Covid-19 Times: Is Going Remote the... - Labiotech.eu

Recommendation and review posted by Bethany Smith

With a multi-disciplinary approach, Fact.MR elaborates an extensive analysis of the historical, current and future outlook of the global Gene Therapy market as well as the factors responsible for such a growth. Our highly dedicated professionals have inputted critical and accurate insights associated with every industry, and region by doing thorough primary and secondary research. The global Gene Therapy market is poised to expand at a CAGR of over xx% during the forecast period (2020-2026).

The recent report on the global Gene Therapy market published by the Fact.MR includes the impact of COVID-19 on the Gene Therapy market. Severe economic crisis are being faced by each and every country of the world. This has affected each and every market in the world and it will take a good amount of time to recover. The Gene Therapy market study includes the current market scenario on the global platform and also forecasts the market development during the forecast period. We leverage space-age industrial and digitalization tools to provide avant-garde actionable insights to our clients regarding the Gene Therapy market. For enhancing readers experience, the report starts with a basic overview about the Gene Therapy and its classification.

Request for Sample Report @ https://www.factmr.com/report/4648/gene-therapy-market

The Gene Therapy market report includes global as well as emerging players:

The insights for each vendor consists of:

Regional Analysis

Important regions covered in the Gene Therapy market report include:

The Gene Therapy market report also provides data regarding the key countries in the defined regions.

Segmentation Analysis

By Product:

By end use:

Send an Enquiry @ https://www.factmr.com/connectus/sample?flag=AE&rep_id=4648

What insights does the Gene Therapy market report provide to the readers?

Questionnaire answered in the Gene Therapy market report include:

And many more

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

Continue reading here:
Impact of COVID-19 Crisis on Gobal Gene Therapy Market Demand and Consumption Growth, Predicts Fact.MR - The Cloud Tribune

Recommendation and review posted by Bethany Smith

AUSTIN, Texas--(BUSINESS WIRE)--Genprex, Inc. (Genprex or the Company) (Nasdaq: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, announced today that it has expanded its program for the manufacture of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for its lead drug candidate, Oncoprex immunogene therapy, by entering into a new agreement with manufacturing partner Aldevron, LLC, (Aldevron). The new agreement provides for production of TUSC2 plasmid DNA, the active agent in Oncoprex, at full commercial scale. The Companys manufacturing at this scale should also result in significantly lower costs per unit of product manufactured due to economies of scale.

Genprexs upcoming clinical trials include a Phase I/II trial of Oncoprex combined with osimertinib (marketed by AstraZeneca as Tagrisso) for non-small cell lung cancer (NSCLC), which received Fast Track Designation in January 2020 and is expected to be initiated in early 2021. A clinical trial of Oncoprex in combination with pembrolizumab (marketed by Merck as Keytruda) in NSCLC is also planned.

We are pleased with continued progress in the scale-up of our manufacturing processes. This new agreement with Aldevron increases our manufacturing capabilities in support of our clinical trials utilizing Oncoprex immunogene therapy in combination with targeted therapies and immunotherapies against lung cancer, said Rodney Varner, Chairman and Chief Executive Officer of Genprex.

Our team is excited about the expansion of our manufacturing agreement and elevation of our long-standing relationship with Genprex, said Michelle Berg, President of GMP Nucleic Acids at Aldevron. Aldevrons GMP facility and campus buildout ensures we can meet the future manufacturing demands of companies experiencing significant growth such as Genprex; thereby enabling our ultimate goal of impacting the lives of patients.

Oncoprex consists of TUSC2 plasmid DNA encapsulated in a lipid nanoparticle. The TUSC2 gene is the active agent in Oncoprex. Data indicate that the resultant product when transfected into cancer cells both induces cell signaling that triggers programmed cell death and modulates the immune system so that the cancer cells are more susceptible to treatment.

About Aldevron

Aldevron serves the biotechnology industry offering in-stock products and custom production of nucleic acids, proteins, and antibodies. Thousands of clients use Aldevron-produced plasmids, RNA and gene editing enzymes for projects ranging from discovery research to clinical trials to commercial applications. These products are critical raw materials and key components in commercially available drugs and medical devices. Aldevron specializes in GMP manufacturing and is known for inventing the GMP-Source quality system. It is currently constructing a second manufacturing site on its headquarter campus in Fargo, North Dakota, more than doubling its production capacity. It has additional facilities in Madison, Wisconsin, and Freiburg, Germany. To learn more, visit http://www.aldevron.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprexs technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to in-license and develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Companys lead product candidate, Oncoprex, is being evaluated as a treatment for non-small cell lung cancer (NSCLC). Oncoprex has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for Oncoprex immunogene therapy for NSCLC in combination therapy with osimertinib (AstraZenecas Tagrisso) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Companys web site at http://www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprexs product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Companys future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of the effect of our product candidates, alone and in combination with other therapies, on cancer; the timing and success of our clinical trials and planned clinical trials of Oncoprex, alone and in combination with targeted therapies and/or immunotherapies, and whether our other potential product candidates, including our gene therapy in diabetes, advance into clinical trials; the success of our strategic partnerships, including those relating to manufacturing of our products; the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates including whether we receive fast track or similar regulatory designations; costs associated with developing our product candidates and whether patents will ever be issued under patent applications that are the subject of our license agreements. These and other risks and uncertainties are described more fully under the caption Risk Factors and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Read the original post:
Genprex Expands Manufacturing Program with Aldevron to Advance Oncoprex Clinical Development - Business Wire

Recommendation and review posted by Bethany Smith

Researchers at the University of Florida announced Wednesday plans to develop a potential COVID-19 vaccine using a gene therapy approach that has been used to treat rare neuromuscular diseases.

The therapy technique would use a harmless virus, used to package and deliver a gene from SARS-CoV-2 (the virus that causes COVID-19 disease), to help combat a harmful virus. While the gene therapy vaccine is unable to replicate on its own, it is strong enough to trigger virus-neutralizing antibodies against the live virus, according to a UF press release.

Dr. Barry Byrne, a rare-disease researcher and pediatrics professor at UF, has begun testing two vaccine candidates in animal models. Virology experts at UFs Emerging Pathogens Institute anticipate having initial results this month that will determine if the vaccines can induce an effective antivirus response.

The gene therapy technique, which uses a harmless adeno-associated virus (AAV) has been used to develop treatments for other diseases, and researchers are now trying to use AAV to block SARS-CoV-2 virus from entering cells.

Using AAV has some potential advantages over traditional vaccine development, said Dr. Byrne, director of the UF Powell Gene Therapy Center, such as the fact that the therapy has been widely studied so researchers likely wont have to spend as much time testing its safety. It also may take effect rapidly and prove more durable than other types of vaccines.

The research team has tested two closely related vaccine candidates in rodents. By August, Dr. Byrne hopes to start a yearlong trial phase to evaluate the safety and effectiveness of the vaccines in 100 adult volunteers.

Dr. Byrne and his team are striving to develop a universal vaccine to take into account future SARS-CoV-2 genetic drifts and to address the issue of viral mutations that have already been documented. Developing a universal vaccine could take 18 months, according to the universitys press release.

This is a virus that can change very rapidly. That is concerning because it means any vaccine made today may be ineffective tomorrow, Dr. Byrne said.

There are no licensed vaccines that use AAV, but 25 viral vector vaccines are under development. Globally, there are more than 130 vaccine candidates in various stages of development. Both Moderna and Johnson & Johnson have announced that human trials of their vaccine candidates will start in July.

See the original post here:
University of Florida researchers trying to develop universal coronavirus vaccine using gene therapy - Washington Times

Recommendation and review posted by Bethany Smith

Biological Safety Testing Market Scenarios and Brief Analysis with size, status and forecast 2020-2026

The global research report titled Biological Safety Testing Market has recently published by The Research Insights which helps to provide guidelines for the businesses. It has been aggregated on the basis of different key pillars of businesses such as drivers, restraints and global opportunities. This research report has been compiled by using primary and secondary research techniques. While curating this research report several dynamic aspects of businesses such as definition, classification, application, and industrial chain structure have been studied in detail. It sheds light on dynamic aspects of the businesses such as the clients needs and feedback of the various customers. Finally, researchers direct its focus on some significant points to give a gist about investment, profit margin, and revenue.

Get Free Sample Copy of This Report: https://www.theresearchinsights.com/request_sample.php?id=87190

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Biological Safety Testing Market: Lonza Group, SGS SA, WuXiPharmaTech, BSL Bioservice, Merck KGaA, Cytovance Biologics, Toxikon Corporation, Charles River Laboratories International, Sigma-Aldrich Corporation, Avance Biosciences

Global Biological Safety Testing Market Split by Product Type and Applications:

This report segments the global Biological Safety Testing Market on the basis of Types are:

Adventitious Agents Detection Test

Cell Line Authentication and Characterization tests

Bioburden Testing

Endotoxin Tests

Sterility Testing

Residual Host Contaminant Detection Tests

Others

On the basis of Application, the Global Biological Safety Testing Market is segmented into:

Blood Products

Stem Cell Products

Cellular and Gene Therapy Products

Tissue Products

Others

Browse the report description and TOC:

https://www.theresearchinsights.com/life-science/Biological-Safety-Testing-Market-Research-Global-StatusForecast-by-Geography-TypeApplication-2016-2026-87190

Regional analysis of Global Biological Safety Testing Market:

Geographically, the global Biological Safety Testing market has been fragmented into several regions such as North America, Latin America, Asia-Pacific, Africa, and Europe on the basis of productivity of several companies. Each and every segment along with its sub-segments are analyzed in the research report. The competitive landscape of the market has been elaborated by studying numerous factors such as top manufacturers, prices and revenue.

The information on the global Biological Safety Testing market is accessible to readers in logical chapter wise format. Driving and restraining factors have been listed in this research report which helps to provide the understanding of positive as well as negative aspects in front of the businesses.

Key questions answered in this report:

-What are the top key players of the global Biological Safety Testing market?

-What are the strengths of the global Biological Safety Testing market?

-What are the trends, challenges, threats, and opportunities in front of the businesses?

-What are the effective sales methodologies?

-what are the different marketing and distribution channels?

Buy Exclusive Report :

https://www.theresearchinsights.com/checkout?id=87190

Some major points from Table of Content:

Global Biological Safety Testing Market Research Report 2020-2026

Chapter 1: Industry Overview

Chapter 2: Biological Safety Testing Market International and China Market Analysis

Chapter 3: Analysis of Revenue by Classifications

Chapter 4: Analysis of Revenue by Regions and Applications

Chapter 5: Analysis of Biological Safety Testing Industry Key Manufacturers

Chapter 6: Sales Price and Gross Margin Analysis

Chapter 7: Development Trend of Market 2020-2026.

Continued ..

About us:

The Research Insights A global leader in analytics, research and advisory that can assist you to renovate your business and modify your approach. With us, you will learn to take decisions intrepidly. We make sense of drawbacks, opportunities, circumstances, estimations and information using our experienced skills and verified methodologies. Our research reports will give you an exceptional experience of innovative solutions and outcomes. We have effectively steered businesses all over the world with our market research reports and are outstandingly positioned to lead digital transformations. Thus, we craft greater value for clients by presenting advanced opportunities in the global market.

Contact us :

Robin

Sales manager

Contact number: +91-996-067-0000

[emailprotected]

https://www.theresearchinsights.com

Read more:
Biological Safety Testing Market Research, Developments and Precise Outlook 2020 to 2026 - 3rd Watch News

Recommendation and review posted by Bethany Smith

Data Bridge Market Researchhas added an exhaustive research study of theGlobal Choroideremia Treatment Marketdetailing every single market driver and intricately analyzing the business vertical. The research report has abilities to raise as the most significant market worldwide as it has remained playing a remarkable role in establishing progressive impacts on the universal economy. The research report presents a complete assessment of the market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data.

Global Choroideremia Treatment Marketis expected to grow at a steady CAGR in the forecast period of 2019-2026.Increase in strategic alliances between the pharmaceuticals companies and high demand of disease specific novel therapies are the key factors that fueling the market growth. Global Choroideremia Treatment Market By Treatment Type (Gene Therapy, Surgery), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Ophthalmic Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Forecast to 2026

Download exclusive PDF sample report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-choroideremia-treatment-market

Some of the major competitors currently working in the global choroideremia treatment market areBiogen, 4D Molecular Therapeutics, Copernicus Therapeutics, Inc, Wize Pharma Inc, Spark Therapeutics, Inc, PIXIUM VISION, Retina Implant AG, F. Hoffmann-La Roche Ltd and others.

Market Definition:

Choroideremia is also known as choroidal sclerosis is a rare, degenerative, X-linked inherited retinal disorder characterized by progressive degeneration of the choroid, retinal pigment epithelium (RPE) and retina due to Mutations in the CHM gene. This CHM gene required to produce Rab escort protein-1 (REP-1). The condition gets its name from the distinctive sweet odor of affected infants urine and is also c, a protein that takes part in targeting vesicles (small sacs of substances) into, out of, and within cells.

According to the statistics published by U.S. Department of Health & Human Services, an estimated population of choroideremia is about 1 in 50,000-100,000 people. Presence of refined healthcare infrastructure and emerging new market are the key factors for growth of this market.

Market Drivers

Market Restraints

Segmentation:Global Choroideremia Treatment Market

By Treatment

By Route of Administration

By End Users

By Distribution Channel

ByGeography

Download Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-choroideremia-treatment-market

Key Developments in the Market:

Competitive Analysis:

Global choroideremia treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares global choroideremia treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

Order a Copy of Global Choroideremia Treatment Market Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-choroideremia-treatment-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read the original:
Choroideremia Treatment Market 2020 Industry Analysis, Share, Size, Demand, Forecast to grow at a steady CAGR | Copernicus Therapeutics, Inc, Wize...

Recommendation and review posted by Bethany Smith

SAN DIEGO & OSAKA, Japan Neurocrine Biosciences, Inc. (Nasdaq:NBIX) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (Takeda) today announced a strategic collaboration to develop and commercialize compounds in Takedas early-to-mid-stage psychiatry pipeline. Specifically, Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical stage assets for schizophrenia, treatment-resistant depression and anhedonia.

We are excited to collaborate with Takeda to bring life-changing therapies to people living with serious, challenging and under-addressed psychiatric disorders who are in need of better treatment options, said Kevin Gorman, Ph.D., Chief Executive Officer at Neurocrine Biosciences. With our deep understanding in the fields of psychiatry and neurology, we look forward to developing new treatments for schizophrenia, treatment-resistant depression and anhedonia as part of our diverse clinical development pipeline. This strategic partnership enhances our growing pipeline and strengthens our position as a leading neuroscience-focused biopharmaceutical company.

With longstanding experience developing and commercializing therapies for serious neurological and psychiatric disorders, Neurocrine Biosciences is the ideal partner to continue to develop our early-to-mid-stage psychiatry portfolio and bring these potential new therapies to patients, said Sarah Sheikh, M.D., M.Sc., MRCP, Head, Neuroscience Therapeutic Area Unit at Takeda. Takeda is deeply committed to Neuroscience as one of our core therapeutic areas. The strategic partnership with Neurocrine Biosciences allows us to continue to build on our leadership in psychiatry and deliver future medicines for these patients while advancing our clinical assets for rare neurological diseases, such as narcolepsy, developmental and epileptic encephalopathies and neurodegenerative conditions.

Collaboration Details

Under the terms of the agreement, Neurocrine Biosciences will be responsible for developing and commercializing all pipeline compounds included in the collaboration. Takeda will receive a total of $120 million USD in upfront cash. Additionally, Takeda will be entitled to development milestones of up to $495 million USD, commercial milestones of up to $1.4 billion USD and up to double-digit royalties on net sales. At certain development events, Takeda may elect to opt in or out of a 50:50 profit share on all clinical programs on an asset-by-asset basis. For any asset in which Takeda is participating in a 50:50 profit share arrangement, Takeda will not be eligible to receive development or commercial milestones.

Conference Call Information

Today, Neurocrine Biosciences will host a conference call and webcast at 8:00 a.m. ET to provide commentary on the collaboration. The live call may be accessed by dialing (866) 831-8711 (U.S.) or (203) 518-9883 (International) using the conference ID: 5022. A live audio webcast of the conference call will be available online on the Neurocrine Bioscience website under Investors at http://www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Programs in the Collaboration Agreement

TAK-831

TAK-831 is a potential first-in-class D-Amino Acid Oxidase (DAAO) inhibitor that has completed multiple Phase I studies and is currently in on-going Phase II studies, including the Phase II INTERACT proof-of-concept study in negative symptoms of schizophrenia.

TAK-653

TAK-653 is a potential first-in-class Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid (AMPA) potentiator. TAK-653 has completed Phase I studies and is a Phase II study-ready compound with the potential to be developed for treatment-resistant depression.

TAK-041

TAK-041 is a potential first-in-class G Protein-Coupled Receptor 139 (GPR139) agonist. TAK-041 has completed multiple Phase I studies and is a Phase II study-ready compound with the potential to be developed for the treatment of anhedonia in depression. Anhedonia is a psychological condition characterized by the inability to experience pleasure.

Preclinical Programs

The collaboration includes the rights to four preclinical programs.

About Neurocrine Biosciences

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with 28 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The companys diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinsons disease endometriosis* and uterine fibroids* and clinical development programs in multiple therapeutic areas including a gene therapy for Parkinsons disease, chorea in Huntington disease, congenital adrenal hyperplasia, epilepsy and polycystic ovary syndrome*. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

Takedas Commitment to Neuroscience

Takedas Neuroscience therapeutic area is driven by the immense unmet need of patients suffering from neurological diseases. Our mission is to bring innovative and potentially disease-modifying medicines to these patients. Our commitment to patients extends beyond our research and development efforts by supporting several neuroscience patient and provider organizations to raise awareness, educate and broaden access to therapies.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in peoples lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Neurocrine Biosciences Forward-Looking Statements

In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements related to the benefits to be derived from transactions with Takeda Pharmaceutical Company Limited; our potential milestone and royalty payments to Takeda; the development of our product candidates and the timing of completion of our clinical, regulatory, and other development activities. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are: risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and resulting global, national, and local economic and financial disruptions; risks and uncertainties related to any COVID-19 quarantines, shelter-in-place and similar government orders that are currently in place or that may be put in place in the future, including the impact of such orders on our business operations and the business operations of the third parties on which we rely; our future financial and operating performance; risks or uncertainties related to the development of the our product candidates; risks that the FDA or other regulatory authorities may make adverse decisions regarding our product candidates; risks that clinical development activities may not be completed on time or at all; risks that clinical development activities may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks and uncertainties relating to competitive products and technological changes that may limit demand for a product candidate; risks that the benefits of the agreements with Takeda may never be realized; risks that our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in the Companys periodic reports filed with the Securities and Exchange Commission, including without limitation the Companys quarterly report on Form 10-Q for the quarter ended March 31, 2020. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof.

Takeda Pharmaceutical Company Limited Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takedas future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as targets, plans, believes, hopes, continues, expects, aims, intends, ensures, will, may, should, would, could anticipates, estimates, projects or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takedas global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takedas operations and the timing of any such divestment(s); and other factors identified in Takedas most recent Annual Report on Form 20-F and Takedas other reports filed with the U.S. Securities and Exchange Commission, available on Takedas website at: https://www.takeda.com/investors/reports/sec-filings/ or at http://www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takedas future results.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005101/en/

Contacts

Neurocrine Biosciences, Inc.

Media Navjot Rai +1-858-617-7623 media@neurocrine.com

Investors Todd Tushla +1-858-617-7143 ir@neurocrine.com

Takeda Pharmaceuticals

Media in Japan Kazumi Kobayashi +81 (0) 3-3278-2095 kazumi.kobayashi@takeda.com

Media Outside Japan Monique Kelley +1-857-600-3488 monique.kelley@takeda.com

#distro

Follow this link:
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders - Financial Post

Recommendation and review posted by Bethany Smith

The Cell and Tissue Culture Supplies Market research provides a brief analysis comprising both primary and secondary research. The report provides the perception of all the key factors somehow affecting Cell and Tissue Culture Supplies Market. It also includes the degree of competition, product development and opportunities in the global Cell and Tissue Culture Supplies market which makes it more suitable for market analysis. Moreover, the report covers the latest trends, product dynamics, geographical segmentation and regulatory framework regarding Cell and Tissue Culture Supplies market.

Request a Sample Copy of the Report https://www.regalintelligence.com/request-sample/141804

Cell and Tissue Culture Supplies Market prominent players:Stemcell Technologies, Wheaton Industries, GE Healthcare, Thermo Fisher Scientific, VWR International, Merck KGaA, Lonza Group, Corning, Promocell GmbH, Eppendorf AG

Global Cell and Tissue Culture Supplies market report covers all the key players, driving and restraining factors and opportunities in upcoming years. The report provides the historical revenue of the market, latest trends, market size and utilization for the reference regarding the political and technical environment of Cell and Tissue Culture Supplies market share.

Enquire or share your queries if any before purchasing the report-

Market segmentation

Market segmentation by type: Consumable Products, Instruments

Market segmentation by application: Vaccine Production, Biopharmaceutical Production, Toxicity Testing, Gene Therapy, Drug Screening & Development, Cancer Research, Other

Get Detailed Table of [emailprotected] https://www.regalintelligence.com/request-toc/141804

Cell and Tissue Culture Supplies market segmentation by region:

The report provides a brief analysis considering both quality and quantity data predicted to provide opportunities evolving the market growth in the forecasting period. Majorly focusing on factors that might affect the market growth makes it more informative.

Key points covered in Report: The information covered in this report are Introduction, Key findings, Market overview, PEST/SWOT Analysis. Factors affecting the growth, Market Size and Trends, Market Segmentation with regional analysis is also included. Assessment with industry overview, company profile and conclusion is also mentioned respectively.

Important Points from Table of Contents:

Global Cell and Tissue Culture Supplies Market Professional Survey Report 20191 Report Overview1.1 Definition and Specification1.2 Manufacturers and Region Overview1.2.1 Manufacturers Overview1.2.2 Regions Overview1.3 Type Overview1.3.1 Consumable Products1.3.2 Instruments1.4 Application Overview1.4.1 Vaccine Production1.4.2 Biopharmaceutical Production1.4.3 Toxicity Testing1.4.4 Gene Therapy1.4.5 Drug Screening & Development1.4.6 Cancer Research1.4.7 Other1.5 Industrial Chain1.5.1 Cell and Tissue Culture Supplies Industrial Chain1.5.2 Upstream1.5.3 Downstream2.1 The Overall Market Performance(Volume)2.1.1 Consumable Products2.1.2 Instruments2.2 The Overall Market Performance(Value)2.2.1 Consumable Products2.2.2 Instruments3 Global Cell and Tissue Culture Supplies Market Assessment by Application3.1 Overall Market Performance (Volume)3.2 Vaccine Production3.3 Biopharmaceutical Production3.4 Toxicity Testing3.5 Gene Therapy3.6 Drug Screening & Development3.7 Cancer Research3.8 Other4 Competitive Analysis4.1 Stemcell Technologies4.1.1 Stemcell Technologies Profiles4.1.2 Stemcell Technologies Product Information4.1.3 Stemcell Technologies Cell and Tissue Culture Supplies Business Performance4.1.4 SWOT Analysis4.2 Wheaton Industries4.2.1 Wheaton Industries Profiles4.2.2 Wheaton Industries Product Information4.2.3 Wheaton Industries Cell and Tissue Culture Supplies Business Performance4.2.4 SWOT Analysis4.3 GE Healthcare4.3.1 GE Healthcare Profiles4.3.2 GE Healthcare Product Information4.3.3 GE Healthcare Cell and Tissue Culture Supplies Business Performance4.3.4 SWOT Analysis4.4 Thermo Fisher Scientific4.4.1 Thermo Fisher Scientific Profiles4.4.2 Thermo Fisher Scientific Product Information4.4.3 Thermo Fisher Scientific Cell and Tissue Culture Supplies Business Performance4.4.4 SWOT Analysis4.5 VWR International4.5.1 VWR International Profiles4.5.2 VWR International Product Information4.5.3 VWR International Cell and Tissue Culture Supplies Business Performance4.5.4 SWOT Analysis4.6 Merck KGaA4.6.1 Merck KGaA Profiles4.6.2 Merck KGaA Product Information4.6.3 Merck KGaA Cell and Tissue Culture Supplies Business Performance4.6.4 SWOT Analysis4.7 Lonza Group4.7.1 Lonza Group Profiles4.7.2 Lonza Group Product Information4.7.3 Lonza Group Cell and Tissue Culture Supplies Business Performance4.7.4 SWOT Analysis4.8 Corning4.8.1 Corning Profiles4.8.2 Corning Product Information4.8.3 Corning Cell and Tissue Culture Supplies Business Performance4.8.4 SWOT Analysis4.9 Promocell GmbH4.9.1 Promocell GmbH Profiles4.9.2 Promocell GmbH Product Information4.9.3 Promocell GmbH Cell and Tissue Culture Supplies Business Performance4.9.4 SWOT Analysis4.10 Eppendorf AG4.10.1 Eppendorf AG Profiles4.10.2 Eppendorf AG Product Information4.10.3 Eppendorf AG Cell and Tissue Culture Supplies Business Performance4.10.4 SWOT Analysis5 Competitive Lanscape5.1 Global Cell and Tissue Culture Supplies Capacity (K Units) and Market Share of Manufacturers (2014-2020)5.2 Global Cell and Tissue Culture Supplies Sales (K Units) and Market Share of Manufacturers (2014-2020)5.3 Global Cell and Tissue Culture Supplies Revenue (M USD) and Market Share of Manufacturers (2014-2020)5.4 Global Cell and Tissue Culture Supplies Price (USD/Unit) of Manufacturers (2014-2020)5.5 Global Cell and Tissue Culture Supplies Gross Margin of Manufacturers (2014-2020)5.6 Market Concentration

Purchase this Report https://www.regalintelligence.com/buyNow/141804

Thank You.

See the original post here:
Cell and Tissue Culture Supplies Market to Witness Widespread Expansion During 2020 to 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

Prophecy Market Insights Viral Vector and Plasmid DNA Manufacturing market research report focuses on the market structure and various factors affecting the growth of the market. The research study encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Viral Vector and Plasmid DNA Manufacturing market over the forecast period (2019-2029).

The data and information required in the market report are taken from various sources such as websites, annual reports of the companies, journals, and others and were validated by the industry experts. The facts and data are represented in the Viral Vector and Plasmid DNA Manufacturing report using diagrams, graphs, pie charts, and other clear representations to enhance the visual representation and easy understanding the facts mentioned in the report.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3817

The Viral Vector and Plasmid DNA Manufacturing research study contains 100+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The predictions mentioned in the market report have been derived using proven research techniques, assumptions and methodologies. This Viral Vector and Plasmid DNA Manufacturing market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

All the key players mentioned in the Viral Vector and Plasmid DNA Manufacturing market report are elaborated thoroughly based on R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. Also, the report examines, legal policies, and competitive analysis between the leading and emerging and upcoming market trends.

Viral Vector and Plasmid DNA ManufacturingMarket Key Companies:

Segmentation Overview:

Global Viral Vector and Plasmid DNA Manufacturing Market, By Product Type:

Global Viral Vector and Plasmid DNA Manufacturing Market, By Application:

Apart from key players analysis provoking business-related decisions that are usually backed by prevalent market conditions, we also do substantial analysis on market segmentation. The report provides an in-depth analysis of the Viral Vector and Plasmid DNA Manufacturing market segments. It highlights the latest trending segment and major innovations in the market. In addition to this, it states the impact of these segments on the growth of the market.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/3817

Regional Overview:

The survey report includes a vast investigation of the geographical scene of the Viral Vector and Plasmid DNA Manufacturing market, which is manifestly arranged into the localities. The report provides an analysis of regional market players operating in the specific market and outcomes related to the target market for more than 20 countries.

Australia, New Zealand, Rest of Asia-Pacific

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Read more:
Strategic Analysis to Understand the Competitive Outlook of XYZ Market - 3rd Watch News

Recommendation and review posted by Bethany Smith

Global Gene Therapy Marketencompasses an evaluation of distinct parameters that elevate the growth of the global industry. The major topics of globalGene Therapymarket document can be given as: Overview of industry, development, and manufacturing plants analysis, major manufacturers analysis, development trend analysis, manufacturing cost structure analysis, key figures of major manufacturers, market dynamics, segment market analysis by type and by application, and regional market analysis, market forecast for 2020 to 2025 time-period. The report explains market restraints, key drivers, and industry trends that transform the international market either positively or negatively.

NOTE: Our final report will be revised to address COVID-19 effects on the specific market.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/376052/request-sample

Market Analysis And Insights:

Various companies are covered to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Additionally, competitive analysis and trends, mergers & acquisitions, and expansion strategies are derived. The report contains the overall market overview on globalGene Therapymarket dynamics, historic volume and value, robust market methodology, current & future trends, Porters Five Forces Analysis, upstream and downstream industry chain, new technological development, cost structure.

The report focuses on top manufacturers in the global market, involved the assessment of sales, price, revenue, and market share for each manufacturer:Spark Therapeutics LLC, Bluebird Bio, UniQure N.V., Juno Therapeutics, GlaxoSmithKline, Chiesi Farmaceutici S.p.A., Bristol Myers Squibb, Celgene Corporation, Human Stem Cell Institute, Voyager Therapeutics, Shire Plc, Sangamo Biosciences, Dimension Therapeutics and others.

By regions, this report splits the globalGene Therapymarket into several key regions, with sales, revenue, price, and gross margin market share of top players in these regions, like:North America, Europe, Asia Pacific, South America, and the Middle East and Africa.

Based on the end users/applications and product types, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share, and growth rate for each application and product type. Additionally, the report focuses on the product value trends and so the profit margins of each firm among the globalGene Therapyindustry.

BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/global-gene-therapy-market-by-type-germline-gene-376052.html

TheGene TherapyMarket With Respect To The Geographical Terrain:

The report thoroughly examines the market with reference to geographical topography, which divided intoGene Therapy. Details about the sales acquired by each region as well as their market share are discussed in the report. This research highlights key insights that will affect the growth of every region and revenue generated by listed geographies over the projected timeframe.

The overall report presents a study of the global industry trends, historical data, projections for the coming years, and anticipation of compound annual growth rates (CAGRs) by the end of the forecast period. It discovers new market prospects and targeted marketing methodologies for globalGene Therapy. R&D and the demand for new product launches and applications are further discussed. The report includes a study of the market in terms of generic and premium product revenue.

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.

Here is the original post:
Global Gene Therapy Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - Galus Australis

Recommendation and review posted by Bethany Smith

SOUTH SAN FRANCISCO, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (CBIO), today announced final efficacy and safety data from its Phase 2b trial of DalcA, a next-generation subcutaneously (SQ) administered Factor IX (FIX) therapy being developed for the treatment of Hemophilia B. The poster was presented at the World Foundation of Hemophilia Virtual Summit, taking place from June 14 -19, 2020.

The poster, entitled: Phase 2b Trial to evaluate the safety and factor IX levels of a daily subcutaneous prophylaxis treatment regimen of dalcinonacog alfa in Hemophilia B presented by Howard Levy, M.B.B.Ch., Ph.D., M.M.M., chief medical officer, Catalyst Biosciences highlights results from the study.

Data from the trial showed that 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of >12% in all participants, with FIX levels of up to 27% and a half-life of 2.5 to 5.1 days with no bleeds, demonstrating effective prophylaxis and the potential for lower or less frequent dosing. Injection volumes were less than 1 mL. One subject withdrew on day 7 after reporting injection site reactions (ISR) from the first 3 SQ doses. No neutralizing anti-drug antibodies were detected and no serious adverse events were reported. Some subjects reported mild ISR of pain and/or redness, primarily with the initial injections. No thrombotic events occurred and blood coagulation markers of d-dimer, prothrombin fragment 1+2, thrombin-antithrombin and fibrinogen did not show any prothrombotic signals.

The trial data showed excellent efficacy and a clean safety profile, all subjects achieved steady state FIX activity levels exceeding the primary endpoint of 12%. A simple, small volume SQ therapy to provide protective, FIX levels is a potentially transformational improvement in the management of Hemophilia B, said Nassim Usman, Ph.D., president and chief executive officer of Catalyst.

The trial was designed to evaluate daily SQ dosing and the ability to maintain protective steady state FIX levels above 12% in six individuals with severe Hemophilia B. Each subject received a single intravenous dose, followed by daily SQ doses of DalcA for 28 days whereby the pharmacokinetics, pharmacodynamics, safety, tolerability and anti-drug antibody formation were monitored.

A copy of the poster can be accessed on the Events and Presentations section of the Catalyst website.

About Catalyst BiosciencesCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet needs in rare hematologic and systemic complement-mediated disorders. Our protease engineering platform includes development programs in hemophilia, a research program on SQ systemic complement inhibitors and a partnered preclinical development program with Biogen for dry age-related macular degeneration (AMD). One of our key competitive advantages is that the product candidates generated by our protease engineering platform have improved functionality and potency. These characteristics allow for improved dosing of our candidates including SQ systemic administration of recombinant coagulation factors and complement inhibitors, low-dose, high activity gene therapy constructs, and less frequently dosed intravitreal therapeutics. Our most advanced asset, SQ MarzAA has successfully completed Phase 2 development in prophylaxis, significantly reducing the annualized bleed rate (ABR) in individuals with Hemophilia A or B with inhibitors. Following regulatory guidance from the FDA and EMA, we recently announced the design of a Phase 3 registration study that is planned for late 2020. Subcutaneous dalcinonacog alfa (DalcA) is being developed for the treatment of Hemophilia B and has demonstrated efficacy and safety in a Phase 2b clinical trial. We have a discovery stage Factor IX gene therapy construct - CB 2679d-GT - for Hemophilia B, that has demonstrated superiority compared with the Padua variant in preclinical models. Finally, we have a global license and collaboration agreement with Biogen for the development and commercialization of anti-complement Factor 3 (C3) pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry AMD. For more information, please visit http://www.catalystbiosciences.com.

Story continues

Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about the potential for SQ DalcA to transform treatment for patients with Hemophelia B, plans to enroll the begin the Phase 3 trial of MarzAA in late 2020, the potential uses and benefits of MarzAA and DalcA to effectively and therapeutically treat hemophilia subcutaneously, the superiority of CB 2679d-GT over other gene therapy candidates and the Companys collaboration with Biogen for the development and commercialization of pegylated CB 2782 for the potential treatment of geographic atrophy-associated dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of the COVID-19 virus and other factors, that trials may not have satisfactory outcomes, that additional human trials will not replicate the results from earlier trials, that potential adverse effects may arise from the testing or use of DalcA or MarzAA, including the generation of neutralizing antibodies, which has been observed in patients treated with DalcA, the risk that costs required to develop or manufacture the Companys products will be higher than anticipated, including as a result of delays in development and manufacturing resulting from COVID-19 and other factors, the risk that Biogen will terminate Catalysts agreement, competition and other risks described in the Risk Factors section of the Companys quarterly report filed with the Securities and Exchange Commission on May 11, 2020, and in other filings with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statements, except as required by law.

Contact:Ana KaporCatalyst Biosciences, Inc.investors@catbio.com

Read more from the original source:
Catalyst Biosciences Presents Positive Final Data from its Phase 2b Trial of Subcutaneous Dalcinonacog Alfa (DalcA) at the World Federation of...

Recommendation and review posted by Bethany Smith

Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers comprehensive analysis of the market structure along with estimations of the various segments and sub-segments of the market. This study also analyzes the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors. The company profiles of all the chief and dominating market players and brands who are taking steps such as product launches, joint ventures, mergers and acquisitions are mentioned in the report. With the use of SWOT analysis and Porters Five Forces analysis which are two of the standard, prominent and full-proof methods, this Global Bone Marrow-Derived Stem Cells (BMSCS) Market report is been framed.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

By providing an absolute overview of the market, Global Bone Marrow-Derived Stem Cells (BMSCS) Market report covers various aspects of market analysis, product definition, market segmentation, key developments, and the existing vendor landscape. Such market insights can be accomplished with this comprehensive Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report which takes into account all the aspects of current and future market. The report provides wide-ranging analysis of the market structure along with the estimations of the various segments and sub-segments of the market. This Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers an analytical measurement of the main challenges faced bythe business currently and in the upcoming years.

Bone marrow-derivedstem cells(BMSCS) marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.4% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of bone marrow derived stem cells will boost the growth of the market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

The major players covered in the bone marrow-derived stem cells (BMSCS) market report are CBR Systems, Inc, Cordlife Sciences India Pvt. Ltd., Cryo-Cell International, Inc.ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34 among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Some of the factors such as introduction of novel technologies for the preservation of stem cells and their storage, surging investment that will help in research activities leading to stem cells benefits, adoption of hemotopoietic stem cell transplantation system will accelerate the growth of the bone marrow-derived stem cells (BMSCS) market in the forecast period of 2020-2027. Various factors that will create opportunities in the bone marrow-derived stem cells (BMSCS) market are increasing occurrences of various diseases along with rising applications in emerging economies.

Large cost of operation and strict regulatory framework will restrict the growth of bone marrow-derived stem cells (BMSCS) market in the above mentioned forecast period. Ethical concern leading to stem cells will become the biggest challenge in the market growth.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Global Bone Marrow-Derived Stem Cells (BMSCS) Market Scope and Market Size

Bone marrow-derivedstem cells(BMSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Thisbonemarrow-derived stem cells (BMSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on bone marrow-derived stem cells (BMSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Bone Marrow-Derived Stem Cells (BMSCS) Market Country Level Analysis

Bone marrow-derivedstem cells(BMSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The country section of the bone marrow-derivedstem cells(BMSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Bone marrow-derived stem cells (BMSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for bone marrow-derived stem cells (BMSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bone marrow-derived stem cells (BMSCS) market. The data is available for historic period 2010 to 2018.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Key Highlights of Report

Competitive Landscape and Bone Marrow-Derived Stem Cells (BMSCS) Market Share Analysis

Bone marrow-derived stem cells (BMSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to bone marrow-derived stem cells (BMSCS) market.

Get Registered For Digital Conference @https://www.databridgemarketresearch.com/digital-conference/future-of-healthcare-robotics?pm

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more here:
Global Bone Marrow-Derived Stem Cells (BMSCS) Market (COVID 19 Impact Analysis) Data Highlighting Major Vendors, Promising Regions, Anticipated Growth...

Recommendation and review posted by Bethany Smith

This Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report involves a key data and information about the market, emerging trends, product usage, motivating factors for customers and competitors, restraints, brand positioning, and customer behaviour, which is of utmost importance when it comes to achieving a success in the competitive marketplace. Thus, the report deals with plentiful aspects of the industry. This market report provides with CAGR value fluctuation during the forecast period of 2020 2027 for the market. SWOT analysis is the standard, renowned and full-proof method to conduct the market research study which is used to formulate this particular Global Bone Marrow-Derived Stem Cells (BMSCS) Market report.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

By providing an absolute overview of the market, Global Bone Marrow-Derived Stem Cells (BMSCS) Market report covers various aspects of market analysis, product definition, market segmentation, key developments, and the existing vendor landscape. Such market insights can be accomplished with this comprehensive Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report which takes into account all the aspects of current and future market. The report provides wide-ranging analysis of the market structure along with the estimations of the various segments and sub-segments of the market. This Global Bone Marrow-Derived Stem Cells (BMSCS) Market research report delivers an analytical measurement of the main challenges faced bythe business currently and in the upcoming years.

Bone marrow-derivedstem cells(BMSCS) marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to growing at a CAGR of 10.4% in the above-mentioned forecast period. Increasing awareness regarding the benefits associates with the preservation of bone marrow derived stem cells will boost the growth of the market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

The major players covered in the bone marrow-derived stem cells (BMSCS) market report are CBR Systems, Inc, Cordlife Sciences India Pvt. Ltd., Cryo-Cell International, Inc.ESPERITE N.V., LifeCell International Pvt. Ltd., StemCyte India Therapeutics Pvt. Ltd, PerkinElmer Inc, Global Cord Blood Corporation., Smart Cells International Ltd., Vita 34 among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Some of the factors such as introduction of novel technologies for the preservation of stem cells and their storage, surging investment that will help in research activities leading to stem cells benefits, adoption of hemotopoietic stem cell transplantation system will accelerate the growth of the bone marrow-derived stem cells (BMSCS) market in the forecast period of 2020-2027. Various factors that will create opportunities in the bone marrow-derived stem cells (BMSCS) market are increasing occurrences of various diseases along with rising applications in emerging economies.

Large cost of operation and strict regulatory framework will restrict the growth of bone marrow-derived stem cells (BMSCS) market in the above mentioned forecast period. Ethical concern leading to stem cells will become the biggest challenge in the market growth.

Global Bone Marrow-Derived Stem Cells (BMSCS) Market By Service Type (Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation), Application (Personalized Banking Applications, Research Applications, Clinical Applications), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa), Market Trends and Forecast to 2027

Global Bone Marrow-Derived Stem Cells (BMSCS) Market Scope and Market Size

Bone marrow-derivedstem cells(BMSCS) market is segmented on the basis of service type and application. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Thisbonemarrow-derived stem cells (BMSCS) market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on bone marrow-derived stem cells (BMSCS) market contactData Bridge Market Researchfor anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Bone Marrow-Derived Stem Cells (BMSCS) Market Country Level Analysis

Bone marrow-derivedstem cells(BMSCS) market is analysed and market size insights and trends are provided by country, service type and application as referenced above.

The country section of the bone marrow-derivedstem cells(BMSCS) market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Bone marrow-derived stem cells (BMSCS) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipments, installed base of different kind of products for bone marrow-derived stem cells (BMSCS) market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the bone marrow-derived stem cells (BMSCS) market. The data is available for historic period 2010 to 2018.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-bone-marrow-derived-stem-cells-bmscs-market

Key Highlights of Report

Competitive Landscape and Bone Marrow-Derived Stem Cells (BMSCS) Market Share Analysis

Bone marrow-derived stem cells (BMSCS) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies focus related to bone marrow-derived stem cells (BMSCS) market.

Get Registered For Digital Conference @https://www.databridgemarketresearch.com/digital-conference/future-of-healthcare-robotics?pm

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Read more here:
Global Bone Marrow-Derived Stem Cells (BMSCS) Market Analysis 2020 With COVID 19 Impact Analysis| Leading Players, Industry Updates, Future Growth,...

Recommendation and review posted by Bethany Smith

The "Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts by Type; Treatment; Application; End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

The stem cell therapy market was valued at US$ 1,534.55 million in 2019 and is estimated to reach US$ 5,129.66 million by 2027; it is expected to grow at a CAGR of 16.7% from 2020 to 2027.

The increasing awareness related to the stem cells therapy in effective disease management and growing demand for regenerative medicines are the key factor driving the stem cell therapy market. However, high cost related of the stem cell therapy limits the growth of the market.

Stem cell research has been widely investigated globally for various medical applications, especially for the treatment of humans. This raises the importance of creating public awareness about stem cell research and its clinical potential. The main role of stem cells is in the replacement of dying cells and reconstruction of damaged tissues. Based on the extensive stem cell research, many scientists have claimed that these cells could probably be used in the treatment of various diseases, including cancer and cardiovascular disease.

There is a large number of potential treatment procedures that are undergoing clinical trials, and a notably few stem cell therapies have won FDA (i.e., US -Food and Drug Administration) approval for clinical usage. For instance, in 2019, the FDA approved Fedratinib for the first-line treatment for myelofibrosis. Moreover, stem cell therapies are widely used in bone marrow transplantation, and these therapies have benefited thousands of people suffering from leukemia. Hematopoietic stem cells are used for treating more than 80 medical diseases, including immune system disorders, blood disorders, neurological disorders, metabolic disorders, genetic disorders, and several types of cancers, such as leukemia and lymphoma; this is also likely to boost the demand for this treatment procedure during the forecast period. Researchers are further investigating the use of stem cell therapies in the treatment of autoimmune disorders.

The global stem cell therapy market has been segmented on the basis of type, treatment, application type, and end user. Based on type, the market has been segmented into adult stem cell therapy, induced pluripotent stem cell therapy, embryonic stem cell therapy, and others. The adult stem cell therapy held the largest share of the market in 2019; however, induced pluripotent stem cell therapy is estimated to register the highest CAGR in the market during the forecast period. Based on treatment, the stem cell therapy market has been segmented into allogeneic and autologous. The allogeneic segment held a larger share of the market in 2019; however, the market for the autologous segment is expected to grow at a higher CAGR during the forecast period.

Reasons to Buy:

Market Dynamics

Drivers

Restraints

Opportunities

Future Trends

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/kn7iuy

View source version on businesswire.com: https://www.businesswire.com/news/home/20200615005447/en/

Contacts

ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470For U.S./CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900

See the article here:
Stem Cell Therapy Market to 2027 - Global Analysis and Forecasts - ResearchAndMarkets.com - Yahoo Finance

Recommendation and review posted by Bethany Smith

When Dr Yendry Ventura began work to set up the Abu Dhabi Stem Cell Centre in late 2018, there was, he says, nothing else "related to stem cell therapy in the emirate.

Fast forward to today and the situation has changed dramatically. After opening in December last year, the centre has already received international press coverage over to its research into a treatment for Covid-19.

Their groundbreaking work has involved taking stem cells from a patients blood and returning them, via a nebuliser, as a fine mist to the lungs.

There they help regenerate lung cells and improve the body's immune response by preventing an overreaction to the infection that can damage healthy cells.

What characterises the method, says Dr Ventura, is that very little manipulation of the cells is needed for the treatment to be effective.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

Dr Yendry Ventura

We separate a specific layer of cells from the blood, Dr Ventura told The National. Were the first one to use these cells with this route with this method.

We believe this way the cells can be aimed much better to the affected organs - the upper and lower respiratory tract.

In April, the centres efforts to develop a Covid-19 treatment led to the recovery of all 73 patients the treatment was initially trialled on. A quarter had been in intensive care.

The results appeared so promising that this month the centre secured intellectual property rights to the technique, allowing the treatment to be widely licensed, including to facilities abroad.

The ongoing work exemplifies how the centres specialists have been able to apply their expertise to help in a time of crisis, Dr Ventura said.

But the new research is a departure from the facilitys usual purpose, which involves developing cutting-edge stem cell treatments for conditions such as cancer and heart disease.

Stem cells were first extracted from humans and grown in laboratories less than a quarter of a century ago.

The human body is mostly made of specialised cell types, such as heart muscle cells, kidney cells or nerve cells, all of which have a particular form related to their function.

Stem cells, however, have not yet undergone the process of developing into a specialised cell type, and are able to be manipulated to perform a specific function.

In adults, stem cells are found in tissues including fat and bone marrow, and these can be turned into cell types.

One technique that the Abu Dhabi Stem Cell Centre plans to implement is haematopoietic stem cell transplantation, which involves stem cells being removed from an individual who is due to have cancer treatment.

The cells are then processed in a laboratory and injected into the patient after they have undergone chemotherapy or radiotherapy.

In this way, they can replace stem cells destroyed by the treatment, allowing a patient to tolerate a higher dose of therapy.

Dr Ventura says that similar treatments were applicable to most cancers of the blood as well as cancers that produce solid tumours.

There are many of these therapies still in research stage, but if you conquer this research, you can have a programme in which you can ... treat many kinds of cancers at the same time in one centre, he said.

The reality is that cell therapy is curing cancer We need to improve this therapy and make it available for many other people.

The future for the stem cells lies in regenerative medicine, in which you can treat almost all the degenerative conditions.

You can create in the future, if you have the right technologies, even artificial organs.

Set up with private sector funding in collaboration with the UAE authorities, the Abu Dhabi Stem Cell Centre works closely with experts at Sheikh Khalifa Medical City.

But the institution is keen to forge further partnerships with both public and private sector medical institutions.

Currently, it operates seven days a week and has more than 100 staff, including nurses, technicians and doctors who specialise in immunology, haematology, pathology, orthopaedics, urology and radiology.

In another initiative, the facility has recently begun running Minimal Residual Disease tests, which look at how many malignant cells remain in a patients blood or bone marrow.

These tests are useful for people with a variety of blood cancers, including lymphoma, leukaemia and myeloma. But they require fresh samples from the patient, so the lack of UAE testing facilities has, until now, required patients to travel abroad.

We try to implement the tests here in the Abu Dhabi Stem Cell Centre so that the patient does not need to travel anymore, said Dr Ventura.

Updated: June 16, 2020 02:01 PM

The rest is here:
Coronavirus: inside the UAE stem cell centre working to treat Covid-19 - The National

Recommendation and review posted by Bethany Smith

Hematopoietic Stem Cell Transplantation (HSCT) Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the market Size (Production, Value and Consumption). This Hematopoietic Stem Cell Transplantation (HSCT) industry splits the breakdown (data status 2014-2020 and Six years forecast 2020-2026), by manufacturers, region, type and application. This study also analyses the Hematopoietic Stem Cell Transplantation (HSCT) market Status, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Risks and Entry Barriers, Sales Channels, Distributors and Porters Five Forces Analysis.

Hematopoietic Stem Cell Transplantation (HSCT) Market competitive landscapes provides details by topmost manufactures like (Regen Biopharma Inc, China Cord Blood Corp, CBR Systems Inc, Escape Therapeutics Inc, Cryo-Save AG, Lonza Group Ltd, Pluristem Therapeutics Inc, ViaCord Inc), including Capacity, Production, Price, Revenue, Cost, Gross, Gross Margin, Growth Rate, Import, Export, Market Share and Technological Developments

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures)of Hematopoietic Stem Cell Transplantation (HSCT)[emailprotected]https://www.researchmoz.us/enquiry.php?type=S&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market Competition by Manufacturers (2020 2026): Hematopoietic Stem Cell Transplantation (HSCT) Market Share of Top 3 and Top 5 Manufacturers, Hematopoietic Stem Cell Transplantation (HSCT) Market by Capacity, Production and Share by Manufacturers, Revenue and Share by Manufacturers, Average Price by Manufacturers By Market, Manufacturers Manufacturing Base Distribution, Sales Area, Product Type, Market Competitive Situation and Trends, Market Concentration Rate.

Scope of Hematopoietic Stem Cell Transplantation (HSCT) Market:In 2019, the market size of Hematopoietic Stem Cell Transplantation (HSCT) is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.

In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Hematopoietic Stem Cell Transplantation (HSCT).

On the basis of product type, this report displays the shipments, revenue (Million USD), price, and market share and growth rate of each type.

Allogeneic Autologous

On the basis on the end users/applications,this report focuses on the status and outlook for major applications/end users, shipments, revenue (Million USD), price, and market share and growth rate foreach application.

Peripheral Blood Stem Cells Transplant (PBSCT) Bone Marrow Transplant (BMT) Cord Blood Transplant (CBT)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry[emailprotected]https://www.researchmoz.us/enquiry.php?type=E&repid=2276986

Hematopoietic Stem Cell Transplantation (HSCT) Market: Regional analysis includes:

The Study Objectives Of This Hematopoietic Stem Cell Transplantation (HSCT) Market Report Are:

Contact:

ResearchMozMr. Rohit Bhisey,Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]

Browse More Reports Visit @https://www.mytradeinsight.blogspot.com/

See the original post here:
Hematopoietic Stem Cell Transplantation (HSCT) Market Segments, Opportunity, Growth and Forecast by End-use Idustry 2020-2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

The speed of change is fascinating

As we head into the 2020s, tech developers and medical scientists are working hard to ensure that we stay healthy and well-cared for, for as long as possible. Here are some of the big healthcare innovations making waves at the moment.

Artificial blood has been proposed for a number of years, but it is only recently that it has gained any sort of traction in medical circles. The science behind it is simple to understand while no doubt actually being incredibly complex. Artificial blood does not seek to replace blood entirely but instead to supplement red blood cells in the body, to carry oxygen where it needs to be delivered.

These blood cells are called artificial as they are generated in a lab environment instead of a human body and are grown from stem cells. Researchers typically use hematopoietic stem cells taken from bone marrow for growing such cells. With blood donation dropping, this could be a timely solution to support healthcare professionals alongside blood donation drives.

Blindness is a massive issue no matter where you live on the planet. In particular, corneal blindness is the fourth most common blindness in the world. However, there is now a solution that is cheap and easy to deliver, and that could make a massive difference to many people.

Many are now coming forward to support medical staff in their endeavours in this sector. Tej and Wendy Kohli are key voices in creating help here. Following other charitable givers like Bill and Melissa Gates and Warren Buffett, it is clear that input from top figures like this is crucial in supporting a cause and seeing it develop into a system that could genuinely make a difference.

The ability to use genetic information to come up with a treatment plan for a patient is a precise art. However, research into the world of genomics is making this a much more viable method of treatment than it has previously.

The scope for this is massive. So much of our response to certain treatments can be bound up in our genetics and research here could change medicine forever. With setbacks like organ transplant rejection and gene mutation still having a major impact on medicine as a whole, it is incredibly important that researchers work to find a solution that works around these issues. Comprehensive and detailed genomics might be it.

All three of these areas have seen some massive leaps forward in the past month. No matter what, focus needs to be kept on these key areas in the future. Only then will we see some massive improvements that could shape our healthcare for the better. These developments could lead to the complex becoming the norm in worldwide healthcare.

Developments made today might one day be celebrated as pioneering breakthroughs that helped to transform healthcare and the lives of humanity.

Here is the original post:
Healthcare innovations making waves in 2020 - Crawley Observer

Recommendation and review posted by Bethany Smith

People with cancer may have compromised immunity due to their disease or its treatment. Early reports suggest cancer is a risk factor for severe COVID-19 disease as a result, many patients with cancer, and their families, are concerned about the risks and impacts of COVID-19.

Their concerns and distress are likely to be compounded by extensive media coverage of the pandemic, rapid changes in information about COVID-19 and continuing uncertainty about how to contain the disease.

On top of this, community transmission of COVID-19 has threatened the capacity of cancer services to provide routine investigations and care. In some cases, this has seen a prioritisation or modification of patients cancer therapies.

For example, chemotherapy may be postponed as this can compromise the immune system and make patients more vulnerable to developing COVID-19 disease.

Patients and families may, in turn, be frightened about not receiving proper treatment.

Read more

Another cause for concern is the change in the routine clinical management of cancer patients, partly because patients fear being infected. In Victoria, cancer hospitals have reported a 40 per cent decline in patient presentations for cancer management appointments since the stay-at-home guidelines in late March 2020.

This has raised concern among oncology health professionals about the health and wellbeing of vulnerable cancer patients whose health outcomes are likely to be negatively affected.

As patients are presenting less to hospital, it becomes crucial to develop new ways of identifying any distress in order to provide high-quality cancer management and supportive care.

The restrictions imposed by governments have been effective in limiting the spread of COVID-19, but social distancing, quarantine and visitor limitations have also reduced the opportunity for family support and connection important sources of strength and wellbeing.

These same government restrictions have also increased the use of telehealth to deliver care to cancer patients during COVID-19. Telehealth tools include simple patient health portal messages to relieve triage phone lines, e-consultation and telephone or video-based virtual visits.

Read more

The latest data from the Victorian COVID-19 Cancer Networks Telehealth Expert Group found that all of Victorias health services were now using telehealth for cancer care. And these tools may continue to expand, allowing greater access to supportive care beyond this crisis.

However, as useful as it is, this technology may pose issues of trust, isolation, disconnectedness and worries about abandonment as patients no longer benefit from the reassuring structure of the hospital oncology setting.

Telehealth may also not be possible for patients without a computer or internet access, which may create inequities in psychosocial care.

These issues should be considered if we upscale telehealth procedures for cancer patients and want to keep the best changes after the pandemic.

With respect to COVID-19, people with blood cancer are a particularly vulnerable group and require specialised attention and care. This is because blood cancers affect the production and functions of cells created in the bone marrow, which produces all the cells of our immune system.

Additionally, treatment for blood cancers compromise the immune system further, placing patients at very high risk of opportunistic infections, often for an extended period.

Read more

Even common respiratory viruses, like colds, can threaten survival. As a result, blood cancer specialists have recommended heightened surveillance and protective isolation for people with blood cancers.

A second major issue for blood cancer patients during the COVID-19 pandemic is the availability of donor stem cell products for patients undergoing haematopoietic stem cell transplantation.

Approximately 350 stem cell transplants are performed in Australia every year to treat blood cancers like leukaemia and multiple myeloma.

But finding a suitable stem cell donor is incredibly challenging, and about 80 per cent of donated stem cells come from overseas donors.

Unfortunately, COVID-19 has impacted donor availability due to border restrictions, flight changes and fear of becoming infected, creating very fearful scenarios for those waiting for potentially life-saving stem cell transplantation.

Victoria has already reported a case of a donor cancellation at short notice because the donor was worried about having been in contact with somebody with COVID-19.

The emotional consequences of the COVID-19 pandemic for people with blood cancers cannot be underestimated, nor can the consequences for the healthcare providers who care for them.

Read more

The COVID-19 pandemic has had a serious and disruptive effect.

In the short term, staff and resources at many hospitals have been reassigned to manage the rush of patients with COVID-19. Healthcare providers are faced with ethical dilemmas and required to make difficult treatment decisions without evidence-based guidelines.

Estimating the risk versus the benefit of administering potentially immunosuppressive treatment to patients with haematological cancers with a scarcity of knowledge about this novel disease, and balancing the individual and societal benefits with stretched resources, poses acute ethical dilemmas.

Making these challenging decisions can create fertile grounds for burnout and trauma.

More than ever, we need to develop ways to nurture healthcare providers.

Consideration of their unique experiences and needs during these exceptionally difficult times is important and we need to flexibly develop services to respond to those needs now and beyond this crisis.

But in developing such services, as well as recognising unmet needs, we have to acknowledge the problem-solving skills, resourcefulness and innovation that patients and healthcare providers have already undertaken as they have strived to adapt to managing cancer during COVID-19.

Banner: Getty Images

Read this article:
COVID-19 and cancer care - Pursuit

Recommendation and review posted by Bethany Smith

COVID-19 impact will also be included and considered for forecast.

Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level.

Thalassemia Treatment Market Size Covers Global Industry Analysis, Size, Share, CAGR, Trends, Forecast And Business Opportunity.

>>Need a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Sample

Global Thalassemia Treatment Market 2018-2024Brandessence Market Research is working on a new report titleGlobal Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024?. Rise in number of altered Thalassemia genes, increase in awareness about the disease and high adoption of chelation therapy & blood transfusion for treatment by doctors as well as patients arelikely to enhance the growth of Global Thalassemia Treatment Market.

Scope of Global Thalassemia Treatment Market Reports

Thalassemia is aninherited blood disorder in which the body makes an abnormal form of hemoglobin.People having Thalassemia disease are unable to make sufficient hemoglobin which causes severe anemic conditions.Hemoglobin is found in red blood cells and transports oxygen to all parts of the body. When there is insufficient hemoglobin in the red blood cells, oxygen cannot get to all parts of the body. Organs demand oxygen and are unable to function properly.There are two primary types of Thalassemia disease such as Alpha Thalassemia disease and Beta Thalassemia disease.Alpha Thalassemia results in a formation of additional beta globins, which leads to the formation of beta-globin tetramers (4) called Hemoglobin H.

Beta Thalassemia causesadditionalformation of alpha globins, which develops alpha globin tetramers (a4) that store in the erythroblast (immature red blood cell).Thalassemia is caused by mutations in the DNA of cells that make hemoglobin.

Factors that increase risk of Thalassemia include Family history of thalassemia and certain ancestry.Possible complications of Thalassemia includeIron overload, Infections, Bone deformities, splenomegaly, slowed growth rate of child and Heart problems.

Thalassemia signs and symptoms include Fatigue, Weakness, Pale or yellowish skin, Facial bone deformities, slow growth, abdominal swelling, Dark urine, chest pain,cold hands and feet, poor feeding, greater susceptibility to infections. Diagnosis of Thalassemia includesa complete blood count (CBC), a reticulocyte count,Iron count, Genetic testing and prenatal testing. Treatment of Thalassemia depends on the type and severity of Thalassemia such as Blood transfusions, Bone marrow or stem cell transplant, Surgery and Gene therapy.

Global Thalassemia Treatment Market has been segmented on the basis ofType of Treatment, Diagnosis, End usersand Geography. On the basis of Type of TreatmentGlobal Thalassemia Treatment Market is classified into Blood Transfusion, Chelating Therapy, Bone Marrow Transplant, Stem Cell Transplant, Surgery, Gene Therapy and Others.On the basis of DiagnosisGlobal Thalassemia Treatment Market is classified into Perinatal Testing, Prenatal Testing, Pre-Implantation and Other.On the basis of the End user the Global Thalassemia Treatment Market is classified into Hospitals, Biotechnological Laboratories, Diagnostic Laboratories, Educational Research Institutes, Pharmaceutical Industries and others.

The regions covered in Global Thalassemia Treatment Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market reports cover prominent players like Bluebird bio Inc., Acceleron Pharma Inc., Novartis AG, Celgene Corporation, Shire plc, Bellicum Pharmaceuticals, GlaxoSmithKline Plc, Celgene,Lonza group, Alnylam Pharmaceuticals Inc., Calimmune Inc., CRISPR Therapeutics, Editas Medicine Inc., Errant Gene Therapeutics LLC, Gamida Cell Ltd, Gilead Sciences Inc., Incyte Corp, Ionis Pharmaceuticals Inc., IRBM Science Park SpA, Johnson & Johnson, Kiadis Pharma NV, La Jolla Pharmaceutical Company, Merck & Co Inc., PharmaEssentia Corp, Protagonist Therapeutics Inc., Sangamo Therapeutics Inc., Zydus Cadila Healthcare Ltd, Genorama Ltd, HiMedia Laboratories, DiagCor Bioscience Inc. Ltd and Tosoh Bioscience Inc.

Global Thalassemia Treatment Market Dynamics

Increase in awareness about the disease and technological expansions are likely to raise the adoption of gene therapies. Also Rising Prevalence of Thalassemia, Increase in Pharmaceutical R&D Spending, Increasing Spending on Stem Cell Research, Rising Healthcare Expenditure and Rising Asian Population will boost theGlobal Thalassemia Treatment Market. Treatment of Thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy.Moreover, High operation cost of sophisticated clinical and preclinical imaging systems, High cost of maintenance andless life span of accessoriesalso restraining theGlobal Thalassemia Treatment Market.Yearlyspending for treatment of Thalassemia ranged from $ 108 to 432, depending on type of treatment with average cost per blood transfusion was $ 5.22.2. Average 18.5%14.3 of the total annual income was spent on the treatment for Thalassemia. Drugs prescribed for Thalassemia mostly cures symptoms and side effects such as anemia, iron overload, slow growth of children and vitamin deficiency.Occurrence of Thalassemia is reported to increase steadily over the years across different regions. This can be due to population migration, intermarriages, genetic as well as environmental factors prompting the condition and its implications.Systematic Drugs under Pipeline, Rising Scope for Gene Therapy and increasing awareness towards Thalassemia are some opportunities in the forecast period for theGlobal Thalassemia Treatment Market.

Global Thalassemia Treatment MarketRegional Analysis

North America have largest share ofGlobal Thalassemia Treatment Market. It is mainly driven by quickly increasing immigrant population from tropical regions, rising number of population with Thalassemia carrier gene and rise in birth rates due to variation of genes among the population in the U.S.There are some prenatal tests available on the market to determine the possibility of alpha thalassemia including both invasive and non-invasive technique.

The alpha thalassemia testing market has aemergent trend in the countries with traditional groups like Mediterranean countries, African countries and few countries in Asia Pacific. Furthermore, in Asia Pacific region the growth in similar community marriage practices and high fertility ratewith alpha thalassemia patients have been detected. This is expected to raiseacceptance of blood transfusion and chelation therapy treatments during the forecast period.A latestimprovement in the testing of alpha Thalassemia may determine the risk of the disease by in vitro examination of the embryo. While there are various such tests available in theGlobal Thalassemia Treatment Market but lack of awareness leads to the neglect and delayed diagnosis of the diseased state.

Most frequently prone area for alpha thalassemia is Mediterranean countries, African countries, and Southeast Asian countries. Thalassemia trait practically affects 6% to 35% of the population in these ethnic groups. Middle East & Africa is likely to be the fastest risingGlobal Thalassemia Treatment Market during the forecast period.

Key Benefits for Global Thalassemia Treatment Market Reports

Global Thalassemia Treatment Market report covers in depth historical and forecast analysis.Global Thalassemia Treatment Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.Global Thalassemia Treatment Market report helps to identify opportunities in market place.Global Thalassemia Treatment Market report covers extensive analysis of emerging trends and competitive landscape.Global Thalassemia Treatment Market Segmentation

Global Thalassemia Treatment Market: By Type of Treatment Analysis

Blood TransfusionChelating TherapyBone Marrow TransplantStem Cell TransplantSurgeryGene TherapyOtherGlobal Thalassemia Treatment Market: By Diagnosis Analysis

Perinatal TestingPrenatal TestingPre-ImplantationOtherGlobal Thalassemia Treatment Market: By End user Analysis

HospitalsBiotechnological LaboratoriesDiagnostic LaboratoriesEducational Research InstitutesPharmaceutical IndustriesOtherGlobal Thalassemia Treatment Market: By Regional & Country Analysis

North AmericaU.S.MexicoCanadaEuropeUKFranceGermanyItalyAsia PacificChinaJapanIndiaSoutheast AsiaLatin AmericaBrazilThe Middle East and AfricaGCCAfricaRest of Middle East and AfricaNeed a PDF of the global market report? Visit: https://industrystatsreport.com/Request/Sample?ResearchPostId=57&RequestType=Methodology

Table of Content:

Market Overview: The report begins with this section where product overview and highlights of product and application segments of the Global Thalassemia Treatment Market are provided. Highlights of the segmentation study include price, revenue, sales, sales growth rate, and market share by product.

Competition by Company: Here, the competition in the Worldwide Global Thalassemia Treatment Market is analyzed, By price, revenue, sales, and market share by company, market rate, competitive situations Landscape, and latest trends, merger, expansion, acquisition, and market shares of top companies.

Company Profiles and Sales Data: As the name suggests, this section gives the sales data of key players of the Global Thalassemia Treatment Market as well as some useful information on their business. It talks about the gross margin, price, revenue, products, and their specifications, type, applications, competitors, manufacturing base, and the main business of key players operating in the Global Thalassemia Treatment Market.

Market Status and Outlook by Region: In this section, the report discusses about gross margin, sales, revenue, production, market share, CAGR, and market size by region. Here, the Global Thalassemia Treatment Market is deeply analyzed on the basis of regions and countries such as North America, Europe, China, India, Japan, and the MEA.

Application or End User: This section of the research study shows how different end-user/application segments contribute to the Global Thalassemia Treatment Market.

Market Forecast: Here, the report offers a complete forecast of the Global Thalassemia Treatment Market by product, application, and region. It also offers global sales and revenue forecast for all years of the forecast period.

Research Findings and Conclusion: This is one of the last sections of the report where the findings of the analysts and the conclusion of the research study are provided.

About Us:

We publish market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students.

Read more here:
2025 Projection: Thalassemia Treatment Market Analysis by SWOT, Investment, Future Growth and Major Key Players 2020 to 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

The impetus for the campaign can be traced back to a crime spree in the northern Chinese region of Inner Mongolia. For nearly three decades, the police there investigated the rapes and murders of 11 women and girls, one as young as 8. They collected 230,000 fingerprints and sifted through more than 100,000 DNA samples. They offered a $28,000 reward.

Then, in 2016, they arrested a man on unrelated bribery charges, according to the state news media. Analyzing his genes, they found he was related to a person who had left his DNA at the site of the 2005 killing of one of the women. That person, Gao Chengyong, confessed to the crimes and was later executed.

Mr. Gaos capture spurred the state media to call for the creation of a national database of male DNA. The police in Henan Province showed it was possible, after amassing samples from 5.3 million men, or roughly 10 percent of the provinces male population, between 2014 and 2016. In November 2017, the Ministry of Public Security, which controls the police, unveiled plans for a national database.

China already holds the worlds largest trove of genetic material, totaling 80 million profiles, according to state media. But earlier DNA gathering efforts were often more focused. Officials targeted criminal suspects or groups they considered potentially destabilizing, like migrant workers in certain neighborhoods. The police have also gathered DNA from ethnic minority groups like the Uighurs as a way to tighten the Communist Partys control over them.

The effort to compile a national male database broadens those efforts, said Emile Dirks, an author of the report from the Australian institute and a Ph.D. candidate in the department of political science at the University of Toronto. We are seeing the expansion of those models to the rest of China in an aggressive way that I dont think weve seen before, Mr. Dirks said.

In the report released by the Australian institute, it estimated that the authorities aimed to collect DNA samples from 35 million to 70 million men and boys, or roughly 5 percent to 10 percent of Chinas male population. They do not need to sample every male, because one persons DNA sample can unlock the genetic identity of male relatives.

Read the original here:
China Is Collecting DNA From Tens of Millions of Men and Boys, Using U.S. Gear - The New York Times

Recommendation and review posted by Bethany Smith